941PDAn investigator initiated, open label, randomized, controlled, multicentric study, to assess the safety and efficacy of nimotuzumab (BIOMAb-EGFR) concurrent with cisplatin and radiotherapy (RT) in histologically documented squamous cell carcinoma of the cervix
2017
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI